A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form
Munde Manojkumar K.1,2,*, Kulkarni Nilesh S.2, Rukhe Nikita B.2, Sen Dhanya B.1
1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India
2PES Modern College of Pharmacy (for Ladies), Moshi, Pune-412105, Maharashtra, India. Affiliated to Savitribai Phule Pune University, Pune
*Corresponding Author E-mail: firstname.lastname@example.org
Online published on 10 August, 2020.
SGLT-2 is the newly developed class of antidiabetic medicine also called as gliflozins. Empagliflozin, dapagliflozin and canagliflozin are the SGLT-2 class inhibitors for the treatment of type II diabetes mellitus. SGLT-2 inhibitors shows the 82% of plasma protein binding, 36.8% of partitioning of red blood cells, 78% of bioavailability, 5.6 to 13.1 hrs half life in oral route of administration. In this review we complied analytical methods for the development and determination of the SGLT-2 inhibitors. Table no. 1, 2, 3 shows the analytical method development and validation of empagliflozin dapagliflozin and canagliflozin alone and with its combination by the HPLC method respectively also table no. 4 shows the various formulations available in SGLT-2 Inhibitors.
Empagliflozin, dapagliflozin, canagliflozin, pharmacokinetic parameters, pharmacodynamic parameters, HPLC method.